EP0682519A4 - Inhibiteurs de l'adenosine kinase. - Google Patents

Inhibiteurs de l'adenosine kinase.

Info

Publication number
EP0682519A4
EP0682519A4 EP94909558A EP94909558A EP0682519A4 EP 0682519 A4 EP0682519 A4 EP 0682519A4 EP 94909558 A EP94909558 A EP 94909558A EP 94909558 A EP94909558 A EP 94909558A EP 0682519 A4 EP0682519 A4 EP 0682519A4
Authority
EP
European Patent Office
Prior art keywords
kinase inhibitors
adenosine kinase
adenosine
inhibitors
kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94909558A
Other languages
German (de)
English (en)
Other versions
EP0682519A1 (fr
Inventor
Gary Steven Firestein
Bheemarao Ganapatrao Ugarkar
Leonard Paul Miller
Harry Edward Gruber
David Andrew Bullough
Mark David Erion
Angelo John Castellino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sicor Inc
Original Assignee
Sicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sicor Inc filed Critical Sicor Inc
Publication of EP0682519A1 publication Critical patent/EP0682519A1/fr
Publication of EP0682519A4 publication Critical patent/EP0682519A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP94909558A 1993-02-03 1994-02-03 Inhibiteurs de l'adenosine kinase. Withdrawn EP0682519A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1419093A 1993-02-03 1993-02-03
PCT/US1994/001340 WO1994017803A1 (fr) 1993-02-03 1994-02-03 Inhibiteurs de l'adenosine kinase
US14190 2001-11-13

Publications (2)

Publication Number Publication Date
EP0682519A1 EP0682519A1 (fr) 1995-11-22
EP0682519A4 true EP0682519A4 (fr) 1997-12-17

Family

ID=21764031

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94909558A Withdrawn EP0682519A4 (fr) 1993-02-03 1994-02-03 Inhibiteurs de l'adenosine kinase.

Country Status (4)

Country Link
EP (1) EP0682519A4 (fr)
AU (1) AU6236594A (fr)
IL (1) IL108523A0 (fr)
WO (1) WO1994017803A1 (fr)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5864033A (en) * 1989-09-15 1999-01-26 Metabasis Therapeutics, Inc. Adenosine kinase inhibitors
US5726302A (en) * 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
US5763596A (en) * 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. C-4' modified adenosine kinase inhibitors
US5674998A (en) * 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
US5763597A (en) * 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. Orally active adenosine kinase inhibitors
US5795977A (en) * 1989-09-15 1998-08-18 Metabasis Therapeutics, Inc. Water soluble adenosine kinase inhibitors
US5721356A (en) * 1989-09-15 1998-02-24 Gensia, Inc. Orally active adenosine kinase inhibitors
ATE159257T1 (de) * 1994-05-03 1997-11-15 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer wirkung
US6395733B1 (en) 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
US5665721A (en) * 1995-06-07 1997-09-09 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
US6143749A (en) * 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
BR9609467A (pt) * 1995-07-11 1999-03-02 Astra Pharma Prod Composto uso de um composto composição farmacéutica e processos para preparação de um composto e tratamento de distúrbios de agregação planquetária
JP4275733B2 (ja) * 1996-01-23 2009-06-10 ノバルティス アクチエンゲゼルシャフト ピロロピリミジンおよびその製造法
JP4255138B2 (ja) * 1996-05-24 2009-04-15 湧永製薬株式会社 脳疾患治療剤
WO1998001459A1 (fr) * 1996-07-05 1998-01-15 Novo Nordisk A/S Nouveaux derives de n-alcoxyadenine inhibant la cytokine
US5824657A (en) * 1997-03-18 1998-10-20 Cubist Pharmaceuticals, Inc. Aminoacyl sulfamides for the treatment of hyperproliferative disorders
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
CA2234342A1 (fr) * 1997-04-10 1998-10-10 Kyowa Hakko Kogyo Co., Ltd. Remede pour la pancreatite
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
NZ510588A (en) * 1998-09-18 2003-08-29 Abbott Gmbh & Co Pyrrolopyrimidines as protein kinase inhibitors
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
US7071199B1 (en) 1999-09-17 2006-07-04 Abbott Gmbh & Cco. Kg Kinase inhibitors as therapeutic agents
CZ2002936A3 (cs) 1999-09-17 2002-10-16 Abbott Gmbh & Co. Kg Pyrazolopyrimidiny jako terapeutické prostředky
BR0016415A (pt) * 1999-12-16 2002-12-24 Alcon Inc Inibidores de adenosina cinase para o tratamento de dano retinal e de nervo ótico
WO2001072751A1 (fr) * 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines utilisees comme inhibiteurs de tyrosine kinases
GB0100623D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
GB0100622D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds V111
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
EP1615930A2 (fr) 2003-04-09 2006-01-18 Biogen Idec MA, Inc. Triazolotriazines et pyrazolotriazines et leurs procedes de fabrication et d'utilisation
US7674791B2 (en) 2003-04-09 2010-03-09 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
US7834014B2 (en) 2003-04-09 2010-11-16 Biogen Idec Ma Inc. A2a adenosine receptor antagonists
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
WO2006068760A2 (fr) * 2004-11-19 2006-06-29 The Regents Of The University Of California Pyrazolopyrimidines anti-inflammatoires
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
US7585868B2 (en) 2006-04-04 2009-09-08 The Regents Of The University Of California Substituted pyrazolo[3,4-D]pyrimidines as kinase antagonists
CN101842008A (zh) * 2007-08-02 2010-09-22 南方研究所 5’-经取代腺苷、其制备和作为s-腺苷甲硫氨酸脱羧酶抑制剂的用途
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
JP5498392B2 (ja) 2007-11-30 2014-05-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用
WO2009088990A1 (fr) 2008-01-04 2009-07-16 Intellikine, Inc. Entités chimiques, compositions et procédés
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
PT3133080T (pt) * 2008-01-18 2018-11-16 Inst Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Nucleósidos de 7-deazapurina citostáticos inovadores
WO2009114874A2 (fr) 2008-03-14 2009-09-17 Intellikine, Inc. Inhibiteurs de kinases (benzothiazole) et procédés d’utilisation associés
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
WO2010006072A2 (fr) 2008-07-08 2010-01-14 The Regents Of The University Of California Modulateurs de mtor et leurs utilisations
CN102124009B (zh) 2008-07-08 2014-07-23 因特利凯公司 激酶抑制剂及其使用方法
GB0815968D0 (en) * 2008-09-03 2008-10-08 Angeletti P Ist Richerche Bio Antiviral agents
WO2010026214A1 (fr) 2008-09-08 2010-03-11 Boehringer Ingelheim International Gmbh Pyrazolopyrimidines et leur utilisation pour le traitement de troubles du snc
WO2010036380A1 (fr) 2008-09-26 2010-04-01 Intellikine, Inc. Inhibiteurs hétérocycliques de kinases
DK2358720T3 (en) 2008-10-16 2016-06-06 Univ California Heteroarylkinaseinhibitorer fused-ring
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
JP2012521359A (ja) * 2009-03-20 2012-09-13 アリオス バイオファーマ インク． 置換されたヌクレオシドアナログおよびヌクレオチドアナログ
PL2414363T3 (pl) 2009-03-31 2014-06-30 Boehringer Ingelheim Int Pochodne 1-heterocyklilo-1,5-dihydro-pirazolo[3,4-d]pirymidyn-4-onu i ich zastosowanie jako modulatorów PDE9A
NZ700583A (en) * 2009-04-22 2016-04-29 Acad Of Science Czech Republic Novel 7-deazapurine nucleosides for therapeutic uses
WO2010129816A2 (fr) 2009-05-07 2010-11-11 Intellikine, Inc. Composés hétérocycliques et leurs utilisations
WO2011047384A2 (fr) 2009-10-16 2011-04-21 The Regents Of The University Of California Procédés d'inhibition de l'activité ire1
WO2011146882A1 (fr) 2010-05-21 2011-11-24 Intellikine, Inc. Composés chimiques, compositions et procédés pour modulation de kinases
UA110347C2 (uk) 2010-08-12 2015-12-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх ПОХІДНІ 6-ЦИКЛОАЛКІЛ-1,5-ДИГІДРОПІРАЗОЛО[3,4-d]ПІРИМІДИН-4-ОНУ І ЇХ ЗАСТОСУВАННЯ ЯК ІНГІБІТОРІВ PDE9A
WO2012040127A1 (fr) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Analogues nucléotidiques substitués
EP2637669A4 (fr) 2010-11-10 2014-04-02 Infinity Pharmaceuticals Inc Composés hétérocycliques et utilisations de ceux-ci
NZ612909A (en) 2011-01-10 2015-09-25 Infinity Pharmaceuticals Inc Processes for preparing isoquinolinones and solid forms of isoquinolinones
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
AR085397A1 (es) 2011-02-23 2013-09-25 Intellikine Inc Combinacion de inhibidores de quinasa y sus usos
TWI565709B (zh) 2011-07-19 2017-01-11 英菲尼提製藥股份有限公司 雜環化合物及其用途
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AR091790A1 (es) 2011-08-29 2015-03-04 Infinity Pharmaceuticals Inc Derivados de isoquinolin-1-ona y sus usos
JP6342805B2 (ja) 2011-09-02 2018-06-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途
CA2860234A1 (fr) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Analogues de nucleotide phosphorothioate substitue
NZ631601A (en) 2012-03-21 2016-06-24 Alios Biopharma Inc Solid forms of a thiophosphoramidate nucleotide prodrug
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
SG11201502331RA (en) 2012-09-26 2015-04-29 Univ California Modulation of ire1
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
EP2976086B1 (fr) 2013-03-22 2020-10-14 Millennium Pharmaceuticals, Inc. Combinaison d'inhibiteurs catalytiques de mtorc1/2 et inhibiteurs sélectifs de la kinase aurora a
EA201690713A1 (ru) 2013-10-04 2016-08-31 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения и их применения
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2943075C (fr) 2014-03-19 2023-02-28 Infinity Pharmaceuticals, Inc. Composes heterocycliques destines a etre utilises dans le traitement de troubles medies par pi3k-gamma
WO2015160975A2 (fr) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Polythérapies
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
AU2014277740B1 (en) * 2014-12-17 2016-02-25 Institute of Organic Chemistry and Biochemistry, ASCR, v.v.i. Novel substituted 7-deazapurine ribonucleosides for therapeutic uses
NZ740616A (en) 2015-09-14 2023-05-26 Infinity Pharmaceuticals Inc Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (fr) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues de composés isoquinolinone et quinazolinone et leurs utilisations comme inhibiteurs de la kinase pi3k
WO2017214269A1 (fr) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
CN109640999A (zh) 2016-06-24 2019-04-16 无限药品股份有限公司 组合疗法
EP3541396A4 (fr) * 2016-11-18 2020-07-22 Arcus Biosciences, Inc. Inhibiteurs de l'immunosuppression médiée par cd73
CN110687232A (zh) * 2018-07-04 2020-01-14 郑州泰丰制药有限公司 用高效液相色谱检测l-氯糖差向异构体的方法
US20220152072A1 (en) * 2019-04-05 2022-05-19 Prelude Therapeutics, Incorporated Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990009163A2 (fr) * 1989-01-24 1990-08-23 Gensia Pharmaceuticals, Inc. Procede et composes de liberation d'aica-riboside et de reduction du taux de glucose dans le sang
WO1992002214A1 (fr) * 1990-08-10 1992-02-20 Gensia Pharmaceuticals, Inc. Analogues d'aica riboside
WO1994006438A1 (fr) * 1992-09-11 1994-03-31 The Regents Of The University Of California Analogues de l'adenosine et procede d'intensification de la liberation de l'adenosine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990009163A2 (fr) * 1989-01-24 1990-08-23 Gensia Pharmaceuticals, Inc. Procede et composes de liberation d'aica-riboside et de reduction du taux de glucose dans le sang
WO1992002214A1 (fr) * 1990-08-10 1992-02-20 Gensia Pharmaceuticals, Inc. Analogues d'aica riboside
WO1994006438A1 (fr) * 1992-09-11 1994-03-31 The Regents Of The University Of California Analogues de l'adenosine et procede d'intensification de la liberation de l'adenosine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COTTAM ET AL.: "New Adenosine Kinase Inhibitors with Oral Antiinflammatory Activity: Synthesis and Biological Evaluation.", J. MED. CHEM., vol. 36, 1993, P0C038, pages 3424 - 3430, XP000573807 *
GLORIOSO ET AL.: "Double-blind Multicentre Study of the Activity of S-adenosylmethionine in Hip and Knee Osteoarthritis.", INT. J. CLIN. PHARM. RES., vol. 5, no. 1, 1985, pages 39 - 49, XP000673760 *
See also references of WO9417803A1 *

Also Published As

Publication number Publication date
WO1994017803A1 (fr) 1994-08-18
EP0682519A1 (fr) 1995-11-22
AU6236594A (en) 1994-08-29
IL108523A0 (en) 1994-05-30

Similar Documents

Publication Publication Date Title
EP0682519A4 (fr) Inhibiteurs de l'adenosine kinase.
CY2561B1 (en) Protein kinase C inhibitors
EP0608897A3 (en) Tyrosine kinase inhibitors and benzoylacrylamide derivatives.
IL122335A0 (en) C-4' adenosine kinase inhibitors
GR3029455T3 (en) 3-Aryl-4-hydroxy-3-dihydrofuranone derivatives.
EP0655440A3 (fr) 1-Aminoéthylindoles.
EP0634718A3 (fr) Intégration de systèmes d'ordinateur.
EP0641704A3 (fr) Traîneau à une seule roue.
EP0620222A3 (fr) Tétrahydro-bêta-carbolines.
EP0601322A3 (fr) Inhibiteur de déaminase d'adénosine.
EP0630245A4 (fr) Inhibiteur de la proteine kinase c.
AU7467294A (en) Tyrosine kinase inhibitor
ZA946728B (en) Tocopherois.
EP0620223A3 (fr) Tétrahydropyridoindole.
ZA941137B (en) Substitutet azolone derivatives.
ZA929768B (en) 5-isoquinolinesulfonamide derivatives as protein kinase inhibiting agents.
EP0620043A3 (fr) Appareil pour fragmenter des objets solides.
EP0609763A3 (en) Ph-glasselectrode.
EP0657193A3 (fr) Frein de ski.
ZA949611B (en) Protein kinase C inhibitors
EP0641898A3 (fr) Regard de chaussée.
EP0645218A3 (fr) Tige d'outil.
EP0643916A3 (fr) Mélanges pour pâte à choux.
ZA948297B (en) Pyrimidine derivatives
EP0682714A4 (fr) Nouveaux inhibiteurs de neutrophiles.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950817

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): CH DE FR GB IT LI

A4 Supplementary search report drawn up and despatched

Effective date: 19971031

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): CH DE FR GB IT LI

17Q First examination report despatched

Effective date: 19990331

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010426